Acute Myeloid Leukemia with FLT3 internal tandem duplication mutations (FLT3-ITDmut AML) is an aggressive leukemia character- ized by heterogeneous genetic landscape [1]. Despite significant advances in AML therapy, the relapse rate remains high, due to the emergence of resistant clones, possibly involving leukemic stem cells (LSCs) [2]. This highlights the unmet need for deeper understanding of the molecular and immunophenotypic land- scape of LSCs in FLT3-ITDmut AML. We previously identified a population of leukemic precursor cells (LPCs), present at the time of initial AML diagnosis, characterized by the CD34/CD123/CD25/ CD99+ immunophenotype, and predictive for FLT3-ITDmut positivity [3]. In particular, these cells overexpress CD99 antigen, which may represent a target for monoclonal antibody (mAb) treatment [4].
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML / Travaglini, S.; Ottone, T.; Angelini, D. F.; Fiori, V.; Dominici, S.; Noguera, N. I.; Sniegocka, M.; Antonelli, S.; Irno Consalvo, M. A.; De Bardi, M.; Banella, C.; Divona, M.; Marchesi, F.; Masciarelli, S.; Fazi, F.; Pieraccioli, M.; Palmieri, R.; De Angelis, G.; Buccisano, F.; Venditti, A.; Battistini, L.; Magnani, M.; Voso, M. T.. - In: LEUKEMIA. - ISSN 0887-6924. - 36:6(2022), pp. 1685-1688. [10.1038/s41375-022-01566-5]
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML
Sniegocka M.;Masciarelli S.;Fazi F.;
2022
Abstract
Acute Myeloid Leukemia with FLT3 internal tandem duplication mutations (FLT3-ITDmut AML) is an aggressive leukemia character- ized by heterogeneous genetic landscape [1]. Despite significant advances in AML therapy, the relapse rate remains high, due to the emergence of resistant clones, possibly involving leukemic stem cells (LSCs) [2]. This highlights the unmet need for deeper understanding of the molecular and immunophenotypic land- scape of LSCs in FLT3-ITDmut AML. We previously identified a population of leukemic precursor cells (LPCs), present at the time of initial AML diagnosis, characterized by the CD34/CD123/CD25/ CD99+ immunophenotype, and predictive for FLT3-ITDmut positivity [3]. In particular, these cells overexpress CD99 antigen, which may represent a target for monoclonal antibody (mAb) treatment [4].| File | Dimensione | Formato | |
|---|---|---|---|
|
Travaglini_CD99_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.22 MB
Formato
Adobe PDF
|
1.22 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
